Xstrahl in Action: SARRP Assists in EPR-Mediated Tumor Targeting

 In Life Sciences News

Sorry, this entry is only available in American English. For the sake of viewer convenience, the content is shown below in the alternative language. You may click the link to switch the active language.

In the study, EPR-Mediated Tumor Targeting using Ultrasmall-hybrid Nanoparticles: From Animal to Human with Theranostic AGuIX Nanoparticles, SARRP was used to experience the therapeutic action of enhanced permeability and retention (EPR)-mediated tumor targeting using AGuIX® NPs at low dose specifically when accumulated and activated at the tumor site.

See more below, or the full study here.

Please fill out your details below to download our brochures. Your only need to do once to unlock access.